Continuous Glucose Monitoring in Pregnant Women Undergoing Betamethasone Therapy

Pregnant patients who are undergoing inpatient betamethasone therapy as part of their
clinical care will be eligible for the study. Once the clinical team and patients have
agreed to pursue betamethasone therapy, the patients' treating physician or nurse will
inquire if the patient is interested in participating in our study protocol. Those patients
who are interested in participation will be consented by either a member of the treatment
team or the study team. Prior to receiving the first betamethasone dose, a soft sensor for
continuous glucose monitoring system (CGMS) will be inserted superficially under the skin.
For those patients who will be receiving a scheduled course of betamethasone, the sensor may
be inserted up to 24 hours prior to the betamethasone administration. The patient will be
instructed on how to wear and care for the device. She will wear the CGMS for the duration
of her hospitalization or for up to 7 days total, whichever time period is shorter. For
those patients who are diabetic, they will receive normal finger stick blood glucose (FSBG)
monitoring and insulin therapy as determined by their treating physicians. Those patients
who are not diabetic will need to have 2 FSBG checks each day to correlate with the device.
Abnormal values will be reported to the patients' treating physician and addressed by the
treating physician. Prior to being discharged from the hospital, the patient will have the
device removed. The patient will otherwise be treated routinely. We will record baseline
demographic information and medical history from each of the women. We will also record
information from the neonates' newborn medical records.